ArticleFrontiers in medicine2026
Subconjunctival Injection of Mesenchymal Stem Cells for Corneal Wound Healing After Chemical Injury: Impact on Epithelial Coverage, Limbal Ischemia, and Ocular Surface Inflammatory.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Previous studies in animal models have demonstrated that mesenchymal stem cells (MSCs) are beneficial for reconstructing the ocular surface during corneal wound healing; however, clinical evidence remains scarce. This study aimed to evaluate the clinical safety, feasibility, and preliminary outcomes of subconjunctival umbilical-cord delivered-MSC (UC-MSC) injection as an adjunctive therapy for severe corneal chemical injuries. Methods: This prospective, single-arm clinical case series enrolled six patients with severe corneal chemical injuries. Human UC-MSCs at passages 5-6 were cultured and verified. A total sample of 4 × 10 Results: No localized or systemic adverse events, such as anterior uveitis, progressive ulceration, intraocular infection, or immunological rejection, were observed in any participant. By 4 weeks post-injection, active ocular surface inflammation had significantly decreased in all eyes. Of the five patients with baseline limbal ischemia, four achieved complete revascularization and resolution; the fifth exhibited a marked reduction in ischemia from 100 to 20%. Furthermore, stable corneal re-epithelialization was achieved in five of six eyes, including one with complete paracentral epithelial coverage. Conclusion: Subconjunctival UC-MSC delivery is a safe and feasible adjunctive therapy for managing severe corneal chemical injuries. This cell-based intervention synergizes with conventional therapies to suppress acute inflammation, rescue limbal perfusion while potentially mitigating subsequent corneal neovascularization, and accelerate the structural reconstruction of the ocular surface microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.